BioSpace News Archive

Pharmazz, Inc., a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, announced U.S. Food and Drug Administration clearance of an Investigational New Drug application for a Phase II clinical trial of centhaquine as an adjuvant to the standard of care in critically ill COVID-19 patients with acute respiratory distress syndrome.

Augmedix, Inc. today announced that Laurie McGraw, a former Allscripts Executive, has joined its board of directors, effective March 9, 2022.

aTyr Pharma, Inc. (Nasdaq: LIFE) (aTyr or the “Company”), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the positive outcome of a Type B End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) regarding its lead therapeutic candidate, efzofitimod (ATYR1923), for the treatment of pulmonary sarcoidosis.

Iterum Therapeutics plc announced that the Company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC, granting the Company’s request for a 180-day extension to regain compliance with Nasdaq’s minimum bid price requirement under Nasdaq Listing Rule 5550.

OncoNano Medicine, Inc. today announced two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022 in New Orleans, Louisiana.

Seres Therapeutics to Present at the Oppenheimer 32nd Annual Healthcare Conference.

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, provided an operational update and released financial results for the third fiscal quarter ended January 31, 2022.

Spectrum Pharmaceuticals today announced the appointment of Juhyun Lim to its Board of Directors.

Enzolytics, Inc. announces that Enzolytics IPF Immune, its immune modulator, will be introduced into the U.S. market later this month.

The high prevalence of infectious diseases globally, rapidly aging population, growing demand for point-of-care testing, and home-based lateral flow assay devices are the major factors driving the growth of this market.